Inhibition of Type I Insulin-Like Growth Factor Receptor Signaling Attenuates the Development of Breast Cancer Brain Metastasis

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Saldana, Sandra M ^a,b   Lee, Heng Huan ^a,b   Lowery, Frank J ^a,b   Khotskaya, Yekaterina B ^a   Xia, Weiya ^a   Zhang, Chenyu ^a   Chang, Shih Shin ^a,b   Chou, Chao Kai ^a,b,d   Steeg, Patricia S ^c   Yu, Dihua ^a,b   Hung, Mien Chie ^a,b,d,e  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e ASIA UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

PICROPODOPHYLLIN; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; S6 KINASE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHOSPHORYLATION; BRAIN METASTASIS; BREAST CANCER; CANCER GROWTH; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DRUG TARGETING; EXPERIMENTAL MODEL; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANIMALS; BRAIN; BRAIN NEOPLASMS; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE KNOCKOUT TECHNIQUES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MICE; PHOSPHORYLATION; RECEPTOR, IGF TYPE 1;

EID: 84883549802     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073406     Document Type: Article

References (53)

1. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, et al. (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22: 2865-2872. doi:10.1200/JCO.2004.12.149. PubMed: 15254054.
2. Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS, (2005) Breast cancer metastasis to the central nervous system. Am J Pathol 167: 913-920. doi:10.1016/S0002-9440(10)61180-7. PubMed: 16192626.
3. Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura D, et al. (2011) The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol 8: 344-356. PubMed: 21487419.
4. Cheng X, Hung MC, (2007) Breast cancer brain metastases. Cancer Metastasis Rev 26: 635-643. doi:10.1007/s10555-007-9083-x. PubMed: 17717635.
5. Saunus JM, Momeny M, Simpson PT, Lakhani SR, Da Silva L, (2011) Molecular aspects of breast cancer metastasis to the brain. Genet Res Int, 2011(2011): 219189. PubMed: 22567347.
6. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, et al. (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363: 1665-1672. doi:10.1016/S0140-6736(04)16250-8. PubMed: 15158627.
7. Sperduto PW, Chao ST, Sneed PK, Luo X, Suh J, et al. (2010) Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 77: 655-661. doi:10.1016/j.ijrobp.2009.08.025. PubMed: 19942357.
8. Steeg PS, Camphausen KA, Smith QR, (2011) Brain metastases as preventive and therapeutic targets. Nat Rev Cancer 11: 352-363. doi:10.1038/nrc3053. PubMed: 21472002.
9. Lopez T, Hanahan D, (2002) Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 1: 339-353. doi:10.1016/S1535-6108(02)00055-7. PubMed: 12086849.
10. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM, (2008) The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 14: 6364-6370. doi:10.1158/1078-0432.CCR-07-4879. PubMed: 18927274.
11. Sachdev D, Zhang X, Matise I, Gaillard-Kelly M, Yee D, (2010) The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. Oncogene 29: 251-262. doi:10.1038/onc.2009.316. PubMed: 19838209.
12. Yu H, Rohan T, (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92: 1472-1489. doi:10.1093/jnci/92.18.1472. PubMed: 10995803.
13. Vashisth H, Abrams CF, (2010) All-atom structural models for complexes of insulin-like growth factors IGF1 and IGF2 with their cognate receptor. J Mol Biol 400: 645-658. doi:10.1016/j.jmb.2010.05.025. PubMed: 20488191.
14. Fernandez AM, Torres-Alemán I, (2012) The many faces of insulin-like peptide signalling in the brain. Nat Rev Neurosci 13: 225-239. doi:10.1038/nrn3209. PubMed: 22430016.
15. Kato H, Faria TN, Stannard B, Roberts CT Jr., LeRoith D, (1994) Essential role of tyrosine residues 1131, 1135, and 1136 of the insulin-like growth factor-I (IGF-I) receptor in IGF-I action. Mol Endocrinol 8: 40-50. doi:10.1210/me.8.1.40. PubMed: 7512194.
16. Jackson JG, Zhang X, Yoneda T, Yee D, (2001) Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines. Oncogene 20: 7318-7325. doi:10.1038/sj.onc.1204920. PubMed: 11704861.
17. Yoneda T, Williams PJ, Hiraga T, Niewolna M, Nishimura R, (2001) A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res 16: 1486-1495. doi:10.1359/jbmr.2001.16.8.1486. PubMed: 11499871.
18. Hiraga T, Myoui A, Hashimoto N, Sasaki A, Hata K, et al. (2012) Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer Res, 72: 4238-49. PubMed: 22738911.
19. Sierra A, Price JE, García-Ramirez M, Méndez O, López L, et al. (1997) Astrocyte-derived cytokines contribute to the metastatic brain specificity of breast cancer cells. Lab Invest 77: 357-368. PubMed: 9354770.
20. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, et al. (2008) Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68: 10238-10246. doi:10.1158/0008-5472.CAN-08-2755. PubMed: 19074892.
21. Improta G, Zupa A, Fillmore H, Deng J, Aieta M, et al. (2011) Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation. J Proteome Res 10: 3089-3097. doi:10.1021/pr200065t. PubMed: 21574647.
22. Firth SM, Baxter RC, (2002) Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23: 824-854. doi:10.1210/er.2001-0033. PubMed: 12466191.
23. Schedlich LJ, Graham LD, (2002) Role of insulin-like growth factor binding protein-3 in breast cancer cell growth. Microsc Res Tech 59: 12-22. doi:10.1002/jemt.10173. PubMed: 12242693.
24. Martin JL, Baxter RC, (2011) Signalling pathways of insulin-like growth factors (IGFs) and IGF binding protein-3. Growth Factors 29: 235-244. doi:10.3109/08977194.2011.614237. PubMed: 21895551.
25. Butt AJ, Martin JL, Dickson KA, McDougall F, Firth SM, et al. (2004) Insulin-like growth factor binding protein-3 expression is associated with growth stimulation of T47D human breast cancer cells: the role of altered epidermal growth factor signaling. J Clin Endocrinol Metab 89: 1950-1956. doi:10.1210/jc.2003-030914. PubMed: 15070968.
26. Firth SM, Fanayan S, Benn D, Baxter RC, (1998) Development of resistance to insulin-like growth factor binding protein-3 in transfected T47D breast cancer cells. Biochem Biophys Res Commun 246: 325-329. doi:10.1006/bbrc.1998.8615. PubMed: 9610357.
27. Martin JL, Baxter RC, (1999) Oncogenic ras causes resistance to the growth inhibitor insulin-like growth factor binding protein-3 (IGFBP-3) in breast cancer cells. J Biol Chem 274: 16407-16411. doi:10.1074/jbc.274.23.16407. PubMed: 10347201.
28. O'Han MK, Baxter RC, Schedlich LJ, (2009) Effects of endogenous insulin-like growth factor binding protein-3 on cell cycle regulation in breast cancer cells. Growth Factors 27: 394-408. doi:10.3109/08977190903185032. PubMed: 19919528.
29. Xi Y, Nakajima G, Hamil T, Fodstad O, Riker A, et al. (2006) Association of insulin-like growth factor binding protein-3 expression with melanoma progression. Mol Cancer Ther 5: 3078-3084. doi:10.1158/1535-7163.MCT-06-0424. PubMed: 17172410.
30. Sivaprasad U, Fleming J, Verma PS, Hogan KA, Desury G, et al. (2004) Stimulation of insulin-like growth factor (IGF) binding protein-3 synthesis by IGF-I and transforming growth factor-alpha is mediated by both phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways in mammary epithelial cells. Endocrinology 145: 4213-4221. doi:10.1210/en.2003-1377. PubMed: 15192040.
31. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, et al. (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127. doi:10.1016/j.ccr.2004.06.022. PubMed: 15324695.
32. Lasfargues EY, Coutinho WG, Redfield ES, (1978) Isolation of two human tumor epithelial cell lines from solid breast carcinomas. J Natl Cancer Inst 61: 967-978. PubMed: 212572.
33. Krutzik PO, Nolan GP, (2003) Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A 55: 61-70. PubMed: 14505311.
34. Xia W, Chen JS, Zhou X, Sun PR, Lee DF, et al. (2004) Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res 10: 3815-3824. doi:10.1158/1078-0432.CCR-03-0527. PubMed: 15173090.
35. Martin JL, Lin MZ, McGowan EM, Baxter RC, (2009) Potentiation of growth factor signaling by insulin-like growth factor-binding protein-3 in breast epithelial cells requires sphingosine kinase activity. J Biol Chem 284: 25542-25552. doi:10.1074/jbc.M109.007120. PubMed: 19633297.
36. McCaig C, Perks CM, Holly JM, (2002) Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin. J Cell Sci 115: 4293-4303. doi:10.1242/jcs.00097. PubMed: 12376561.
37. Carbonell WS, Ansorge O, Sibson N, Muschel R, (2009) The vascular basement membrane as "soil" in brain metastasis. PLOS ONE 4: e5857. doi:10.1371/journal.pone.0005857. PubMed: 19516901.
38. Paharkova-Vatchkova V, Lee KW, (2010) Nuclear export and mitochondrial and endoplasmic reticulum localization of IGF-binding protein 3 regulate its apoptotic properties. Endocr Relat Cancer 17: 293-302. doi:10.1677/ERC-09-0106. PubMed: 20228135.
39. Grkovic S, O'Reilly VC, Han S, Hong M, Baxter RC, et al. (2012) IGFBP-3 binds GRP78, stimulates autophagy and promotes the survival of breast cancer cells exposed to adverse microenvironments. Oncogene, 32: 2412-20. PubMed: 22751133.
40. Firth SM, Baxter RC, (1999) Characterisation of recombinant glycosylation variants of insulin-like growth factor binding protein-3. J Endocrinol 160: 379-387. doi:10.1677/joe.0.1600379. PubMed: 10076184.
41. Yoshimine T, Ushio Y, Hayakawa T, Hasegawa H, Arita N, et al. (1985) Immunohistochemical study of metastatic brain tumors with astroprotein (GFAP), a glia-specific protein. Tissue architecture and the origin of blood vessels. J Neurosurg 62: 414-418. doi:10.3171/jns.1985.62.3.0414. PubMed: 3973708.
42. Strömberg T, Ekman S, Girnita L, Dimberg LY, Larsson O, et al. (2006) IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 107: 669-678. doi:10.1182/blood-2005-01-0306. PubMed: 16166596.
43. Girnita A, Girnita L, del Prete F, Bartolazzi A, Larsson O, et al. (2004) Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 64: 236-242. doi:10.1158/0008-5472.CAN-03-2522. PubMed: 14729630.
44. Vasilcanu D, Girnita A, Girnita L, Vasilcanu R, Axelson M, et al. (2004) The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway. Oncogene 23: 7854-7862. doi:10.1038/sj.onc.1208065. PubMed: 15334055.
45. Menu E, Jernberg-Wiklund H, Stromberg T, De Raeve H, Girnita L, et al. (2006) Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood 107: 655-660. doi:10.1182/blood-2005-01-0293. PubMed: 16046527.
46. Conover CA, Powell DR, (1991) Insulin-like growth factor (IGF)-binding protein-3 blocks IGF-I-induced receptor down-regulation and cell desensitization in cultured bovine fibroblasts. Endocrinology 129: 710-716. doi:10.1210/endo-129-2-710. PubMed: 1713161.
47. Duchnowska R, Biernat W, Szostakiewicz B, Sperinde J, Piette F, et al. (2012) Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy. Oncologist 17: 26-35. doi:10.1634/theoncologist.2011-0212. PubMed: 22234627.
48. Gallardo A, Lerma E, Escuin D, Tibau A, Muñoz J, et al. (2012) Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer 106: 1367-1373. doi:10.1038/bjc.2012.85. PubMed: 22454081.
49. Litzenburger BC, Creighton CJ, Tsimelzon A, Chan BT, Hilsenbeck SG, et al. (2011) High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res 17: 2314-2327. doi:10.1158/1078-0432.CCR-10-1903. PubMed: 21177763.
50. Davison Z, de Blacquière GE, Westley BR, May FE, (2011) Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy. Neoplasia 13: 504-515. PubMed: 21677874.
51. Iqbal J, Thike AA, Cheok PY, Tse GM, Tan PH, (2012) Insulin growth factor receptor-1 expression and loss of PTEN protein predict early recurrence in triple-negative breast cancer. Histopathology, 61: 652-659. PubMed: 22759273.
52. Yin S, Girnita A, Strömberg T, Khan Z, Andersson S, et al. (2010) Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. Neuro Oncol 12: 19-27. doi:10.1093/neuonc/nop008. PubMed: 20150364.
53. Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, et al. (2010) Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 16: 5664-5678. doi:10.1158/1078-0432.CCR-10-1564. PubMed: 20829328.